HUMA - Humacyte Inc

Buy Momentum: Bearish

Recent News

Is It Worth Investing in Humacyte, Inc. ( HUMA ) Based on Wall Street's Bullish Views?

Zacks Commentary • 3 weeks, 5 days ago • score: 0.18

According to the average brokerage recommendation (ABR), one should invest in Humacyte, Inc. (HUMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Neutral

Humacyte, Inc. ( HUMA ) Reports Q2 Loss, Misses Revenue Estimates

Zacks Commentary • 1 month ago • score: 0.05

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -60.00% and -73.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Neutral

Humacyte Posts Q2 Revenue Miss

Motley Fool • 1 month ago • score: 0.07

Humacyte ( NASDAQ:HUMA ) , a regenerative medicine company focused on bioengineered human tissues, released its Q2 FY2025 earnings on August 11, 2025. The most notable news from the release was the company's continued operational progress with its lead product Symvess, which saw growing hospital ...

Bullish

Humacyte, Inc. ( HUMA ) Stock Dips While Market Gains: Key Facts

Zacks Commentary • 1 month, 1 week ago • score: 0.23

Humacyte, Inc. (HUMA) concluded the recent trading session at $2.21, signifying a -4.33% move from its prior day's close.

Neutral

Humacyte, Inc. ( HUMA ) Suffers a Larger Drop Than the General Market: Key Insights

Zacks Commentary • 1 month, 2 weeks ago • score: 0.08

Humacyte, Inc. (HUMA) closed at $2.4 in the latest trading session, marking a -1.23% move from the prior day.

Bullish

Humacyte, Inc. ( HUMA ) Stock Dips While Market Gains: Key Facts

Zacks Commentary • 1 month, 2 weeks ago • score: 0.29

Humacyte, Inc. (HUMA) concluded the recent trading session at $2.53, signifying a -5.24% move from its prior day's close.

Bullish

Humacyte, Inc. ( HUMA ) Stock Falls Amid Market Uptick: What Investors Need to Know

Zacks Commentary • 1 month, 3 weeks ago • score: 0.29

Humacyte, Inc. (HUMA) closed at $2.67 in the latest trading session, marking a -2.2% move from the prior day.

Neutral

Humacyte Announces First Symvess™ Sale to Military Treatment Facility - Humacyte ( NASDAQ:HUMA )

Benzinga • 1 month, 3 weeks ago • score: 0.06

Sale follows recent Electronic Catalog ( ECAT ) listing approval by U.S. Defense Logistics Agency Symvess now available to U.S. Department of Defense and U.S. Department of Veterans Affairs facilities DURHAM, N.C., July 23, 2025 ( GLOBE NEWSWIRE ) -- Humacyte, Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

None

52W High

$6.77

52W Low

$1.15

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.87

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

28.57

EV/EBITDA (<8 favorable)

4.34

EV/Revenue (<3 favorable)

248.85

P/S (TTM) (<3 favorable)

276.86

P/B (<3 favorable)

55.89

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

19.74%

Institutions (25–75% balanced)

36.38%

Shares Outstanding

158,372,000

Float

125,188,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

818,000

Gross Profit (TTM)

-80,548,000

EPS (TTM)

-0.47

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-98.76%

ROE (TTM) (>15% strong)

-2.50%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-1.00

Momentum

Bearish momentum

Value

-0.1694

-0.1793

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025